NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 14 December 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien [Chair] Present for all items
2. Dr Peter Selby [Vice Chair] Present for all items
3. Michael Chambers Present for all items
4. Dr David Foreman Present for all items
5. Dr Rob Forsyth Present for all items
6. Dr Natalie Hallas Items 1 to 5.2.2
7. Dr Nigel Langford Present for all items
8. Iain McGowan Items 5 to 7.2.2
9. Kirandip Moyo Items 1 to 5.1.3
10. Dr Mudasar Mushtaq Items 1 to 6.2.2
11. Dr Richard Nicholas Present for all items
12. Ugochi Nwulu Present for all items
13. Stella O’Brien Items 1 to 5.1.3
14. Professor Subhash Pokhrel Present for all items
15. Professor Andrew Renehan Items 1 to 5.2.2
16. Professor Matthew Stevenson Items 1 to 7.1.3
17. Professor Paul Tappenden Present for all items
18. Dr Derek Ward Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Items 1 to 4.2.2 & 6 to 7.2.2

Ross Dent, Associate Director Items 5 to 5.2.2

Gavin Kenny, Project Manager Items 1 to 4.2.2 & 6 to 7.2.2

Louise Jafferally, Project Manager Items 5 to 7.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Health Technology Assessment Adviser Items 5 to 5.2.2

Christian Griffiths, Health Technology Assessment Adviser Items 6 to 6.2.2

Victoria Gillis-Elliott, Health Technology Assessment Analyst Items 1 to 4.2.2

Alan Moore, Health Technology Assessment Analyst Items 5 to 5.2.2

George Millington, Health Technology Assessment Analyst Items 5 to 5.2.2

Sam Slayen, Health Technology Assessment Analyst Items 1 to 5.2.2

Benjamin Gregory, Business Analyst, RIA Items 1 to 6.1.2

Helen Barnett, Senior Medical Editor Items 1 to 4.2.2

Sarah Bromley, Senior Medical Editor Items 5 to 5.2.2

Ruth Melville, Senior Medical Editor Items 7 to 7.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 1 to 4.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment Items 5 to 5.2.2 & 7 to 7.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 5 to 5.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.2.2

Catherine Pank, Assistant Project Manager, COT Items 7 to 7.2.2

Lyn Davies, Coordinator, Corporate Office Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Ismahan Abdullah, Administrator, TA Items 1 to 5.2.2 & 6 to 6.2.2

Iain Cannell, Administrator, TA Items 5 to 5.2.2

Louise Jones, Administrator, TA Items 7 to 7.2.2

Laura Kelly, Administrator, COT Items 1 to 4.2.2

External review group representatives present

Vicky Wakefield, BMJ Group Items 1 to 4.1.3

Mariana Bacelar, BMJ Group Items 1 to 4.1.3

Devarshi Bhattacharyya, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

Sarah Nevitt, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

Joanne Lord, Southhampton Health Technology Assessment Centre Items 6 to 6.1.3

Jonathan Shepherd, Southhampton Health Technology Assessment Centre Items 6 to 6.1.3

Maiwenn Al, Kleijnen Systematic Reviews Ltd Items 7 to 7.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 7 to 7.1.3

Clinical & patient experts present

Dr Parminder Chaggar, Consultant Cardiologist, clinical expert nominated by British Cardiovascular Society, Items 1 to 4.1.3

Nick Hartshorne-Evans, Patient expert nominated by British Cardiovascular Society, Items 1 to 4.1.3

Dr Simon Williams, Consultant Cardiologist clinical expert nominated by Boehringer Ingelheim, Items 1 to 4.1.3

Sarah Worsnop, Patient expert nominated by Boehringer Ingelheim, Items 1 to 4.1.3

Professor Peter Clark, CDF Clinical Lead, NHS England, Items 5 to 5.2.2

Dr David Gilligan, Consultant Oncologist & Associate Lecturer University of Cambridge, clinical expert nominated by Sanofi, Items 5 to 5.1.3

Dr Toby Talbot, Consultant Clinical Oncologist, clinical expert nominated by Sanofi, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 9 November 2021.

### Appraisal of empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from Boehringer Ingelheim
     2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has recently participated in an advisory panel for Pfizer, manufacturer of a possible comparator, but in an unrelated disease area. It was agreed that his declaration does not prevent Michael attending discussions on this appraisal.
* Nominated clinical expert Dr Parminder Chaggar declared financial interests as he has received speaker fees from Boehringer-Ingelheim and AstraZeneca since April 2021. It was agreed that his declaration would not prevent Dr Chaggar from providing expert advice to committee.
* Nominated patient expert Nick Hartshorne-Evans declared direct and indirect financial interests as he is the CEO of the Pumping Marvellous Foundation who in the last 12 months have received educational grants, speaker fees and ad boards from AstraZeneca he was also involved in patient story and patient media day via the Pumping Marvellous Foundation, Disease Awareness Campaign by Boehringer Ingelheim. It was agreed his declaration would not prevent Nick from providing expert advice to committee.
* Nominated clinical expert Dr Simon Williams declared financial interests as he has received honorarium from Boehringer Ingelheim and AstraZeneca for advisory work related to heart failure. It was agreed his declaration would not prevent Dr Williams from providing expert advice to committee.
* Nominated patient expert Sarah Worsnop declared indirect financial interests as in the last 12 months Pumping Marvellous Foundation has received educational grants, speaker fees and ad boards from AstraZeneca. It was agreed her declaration would not prevent Sarah from proving expert advice to committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Kirandip Moyo, Professor Matt Stevenson and Ugochi Nwulu.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10719>

### Appraisal of cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited clinical experts, the National Clinical lead for Cancer drugs fund, external review group representatives, members of the public and company representatives from Sanofi.
     2. The chair asked all committee members, clinical experts, the National Clinical lead for Cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor Matt Stevenson declared financial interests as he has recently advised Sanofi on matters relating to haemophilia treatment, however it was not in this disease area or for cemiplimab. It was agreed that his declaration would not prevent Professor Stevenson from attending discussions on this appraisal.
* Committee member Michael Chambers declared financial interests as he has recently helped co-ordinate a training programme for Roche, who are manufacturer of a possible comparator, however this did not involve consideration of any Roche products. It was agreed that his declaration would not prevent Michael from attending discussions on this appraisal.
* Nominated clinical expert Dr David Gilligan declared direct and indirect financial interests as he is a Trustee of the Roy Castle Lung Cancer Foundation and a member of the British Thoracic Oncology Group [BTOG] Steering Committee and has received remuneration from Sanofi for education & training purposes. It was agreed that his declarations would not prevent Dr Gilligan from providing expert advice to committee.
* Nominated clinical expert Dr Toby Talbot declared financial interests as he has received payments for advisory board activity and for the clinical trial steering group activity regarding cemiplimab in non-small cell lung cancer. It was agreed that his declarations would not prevent Dr Talbot from providing expert advice to committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Derek Ward, Michael Chambers and Ugochi Nwulu.
  1. Part 2 – Closed session [company representatives, clinical experts, external review group representatives and members of the public were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10725>

### Appraisal of solriamfetol for treating excessive waketime sleepiness caused by obstructive sleep apnoea [ID1499]

* 1. Part 1 – Closed session [No public in attendance]
     1. The chair Professor Stephen O’Brien welcomed, the external review group representatives, and company representatives from Jazz Pharmaceuticals.
     2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Richard Nicholas declared financial interests as he has attended paid advisory boards for Novartis, Biogen, and Roche in the field of multiple sclerosis treatments. It was agreed that his declaration would not Richard from participating in discussion on this appraisal.
* Committee member Michael Chambers declared financial interests as he has provided consultancy advice to Shire Pharmaceuticals [manufacturer of a potential comparator therapy], in disease areas unrelated to this appraisal and most recently in late 2017. Shire is now part of Takeda Pharmaceuticals, with whom he currently has a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again unrelated to the topic of this appraisal.it was agreed that his declaration would not prevent Michael from participating in discussion on this appraisal.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session [company representatives and external review group representatives were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10385>

### Appraisal of pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]

* 1. Part 1 – Closed session [No public in attendance]
     1. The chair Professor Stephen O’Brien welcomed, the external review group representatives, and company representatives from BioProjet.
     2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has provided consultancy advice to Shire Pharmaceuticals in disease areas in an unrelated area, most recently in late 2017. Shire is now part of Takeda Pharmaceuticals, with whom I currently have a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again in an unrelated area of this appraisal. It was agreed that his declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
* Dr Richard Nicholas declared financial interests as he has been paid advisory boards for Novartis for treatments in an unrelated area [MS]. It was agreed that his declaration would not prevent Dr Nicholas from participating in this section of the meeting.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session [company representatives and external review group representatives were asked to leave the meeting].
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10725>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 11 January 2022 and will start promptly at 09.30.